Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels

Detalles Bibliográficos
Autores principales: Dobi, Anthony, Dubernet, Arthur, Rakoto, Mahary Lalarizo, Seteyen, Anne-Laure Sandenon, Vagner, Damien, Lebeau, Grégorie, Raffray, Loïc, Gasque, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178219/
https://www.ncbi.nlm.nih.gov/pubmed/35679009
http://dx.doi.org/10.1007/s12026-022-09269-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178219/
https://www.ncbi.nlm.nih.gov/pubmed/35679009
http://dx.doi.org/10.1007/s12026-022-09269-w

Ejemplares similares